Highly active antiretroviral therapy and dyslipidemia in people living with HIV/AIDS in Fako Division, South West Region of Cameroon by Dickson Shey Nsagha et al.
RESEARCH ARTICLE Open Access
Highly active antiretroviral therapy and
dyslipidemia in people living with HIV/AIDS
in Fako Division, South West Region of
Cameroon
Dickson Shey Nsagha1*, Elroy Patrick Weledji2, Nguedia Jules Clement Assob3, Longdoh Anna Njunda3,
Elvis Asangbeng Tanue3, Odette Dzemo kibu3, Charlotte Wenze Ayima3 and Marcelin Ngowe Ngowe2
Abstract
Background: The advent of HAART has been associated with a profound reduction in morbidity and mortality
from HIV/AIDS. However, side effects and toxicities associated with HAART may lead to an increased risk for
cardiovascular diseases. The aim of this study was to determine the prevalence of dyslipidemia and determining
factors of derangements in lipid profile associated with the use of HAART regimens in people living with HIV/AIDS
in Fako Division of the South West Region of Cameroon.
Methods: This cross-sectional study was conducted between March and August 2014. Lipid profile was
determined after overnight fast and dyslipidemia diagnosed according to the US National Cholesterol Education
Program III criteria. Socio-demographic characteristics were also collected using a questionnaire. Data was
analyzed using STATA; chi-square test, student’s t-test, ANOVA and logistic regressions were computed.
Results: Two hundred and nine participants were recruited including 157 (75.1 %) on HAART and 52 (24.9 %)
HAART-naïve. Antiretrovirals were drugs containing two nucleoside backbones (zidovudine/ /lamivudine/
tenofovir) with either a non-nucleoside (nevirapine/efavirenz) or a protease inhibitor (lopinavir). No patient was
treated with statins. Their mean age was 43.4 (±11.0) years. The mean CD4+ T cell count was 425 (±281) cells/μl
after mean duration of HIV infection of 54.8 (±43.9) months and mean duration on ART of 63.7 (±41.4) months.
The prevalence of total cholesterol (≥ 200 mg/dL) was 51.0 % in patients on HAART and 9.6 % pre-HAART
patients (p < 0.0001), whereas LDL-cholesterol ≥ 130 mg/dL occurred in 36.9 % and in 7.7 % respectively,
(p = 0.0001). Receiving HAART (adjusted odds ratio =6.24, 95 % CI: 2.33–17.45, p < 0.0001) and HIV duration of
42 months and more (aOR = 2.26, 95 % CI: 1.16–4.42, p = 0.017) were independently associated with total
cholesterol ≥ 200 mg/dL. Receiving HAART (aOR = 5.28, 95 % CI: 1.17–16.32, p = 0.004) was independently
associated with raised LDL-cholesterol values. The adjusted odds ratio (95 % CI) of BMI ≥ 25.0 kg/m2 versus BMI
< 25.0 kg/m2 was 3.25 (1.44–7.34) for triglycerides ≥ 150 mg/dL.
Conclusion: HAART regimens were significantly associated with atherogenic lipid profile. Lipid profile should be
monitored in HIV/AIDS patients on therapy so that any negative effects of HAART are optimally managed.
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Background
The introduction and widespread use of combination anti-
retroviral therapy (ART) referred to as highly active anti-
retroviral therapy (HAART) in the mid 1990’s, has led
HIV-infected individuals to experience a dramatic decline
in immunodeficiency-related events, including causes of
death [1]. The advent of HAART has been associated with
a profound reduction in morbidity and mortality from
HIV/AIDS [2]. However, antiretroviral drugs also have side
effects of varying severity. Disorders of lipid metabolism
associated with HAART have been largely described in
the developed and developing countries, mainly in pa-
tients on treatment regimens including protease inhibitors
(PIs) and stavudine [3]. Treatment regimens including
nevirapine and efavirenz have also been reported to in-
duce lipid derangements [4]. ART can induce raised levels
of total cholesterol (TC), LDL-cholesterol (LDL-c) and tri-
glycerides (TG), and variables effects on HDL-cholesterol
(HDL-c) levels [3]. Also, several reports have documented
increased prevalence of hypertriglyceridemia, and low
HDL-c in both HAART-treated and HAART-naïve
patients [5]. Side effects and toxicities are associated with
these highly effective therapies and there is growing con-
cern that the metabolic complications associated with
HIV and antiretroviral therapy may lead to an increased
risk for cardiovascular diseases [6]. These ART-induced
lipid derangements are potentially atherogenic and can
increase cardiovascular risk [7]. There is scarcity of infor-
mation in support of lipid profile derangements associated
with HAART use in sub-Saharan Africa [8]. The aim of
the present study was to determine the prevalence of dys-
lipidemia and determining factors of derangements in
lipid profile associated with the use of HAART regimens
in people living with HIV/AIDS in Fako Division of the
South West Region of Cameroon.
Methods
Study setting and participants
This was a hospital-based cross-sectional study. Partici-
pants were recruited between March and August 2014
at treatment centers of people living with HIV/AIDS
(PLWHA) in the Limbe and Buea Regional Hospitals in
Fako Division, South West Region of Cameroon. Two
groups of participants were selected. Group one was
made up of individuals living with HIV/AIDS who had
been receiving HAART for at least 6 months and re-
ported by the treatment centres as non-defaulters (ART
group). The second group was made up of individuals
newly diagnosed with HIV but who were not yet receiv-
ing HAART (ART-naïve group). All participants were
21 years of age and above. Participants receiving lipid
altering therapies, pregnant women, known diabetes
mellitus patients, those with renal failures and patients
who refused to be part of the study were excluded.
Data collection and measurements
For all participants, structured questionnaires were used to
collect data on the socio-demographic characteristics and
patients’ record were reviewed for information on their
current CD4+ T cell count, HIV and HAART status. Body
mass index and blood pressure were also measured. About
5 ml of venous blood sample was collected from each
participant through venipuncture after a 12 h overnight fast
and centrifuged at 2500 cycles/min for 10 min, and serum
was obtained for fasting blood sugar and lipid profiles
measurements. Fasting blood sugar and lipid profile were
assessed through enzymatic methods (INMESCO, GmbH
(L-S 04/2009) for all participants including total cholesterol
(TC), high density lipoprotein cholesterol (HDL-c), low
density lipoprotein-cholesterol (LDL-c) and triglycerides
(TG). The TC/HDL-c ratio was also calculated. In accord-
ance with the US National Cholesterol Education Program,
Adult Treatment Panel III (NCEP-ATP III) guidelines,
abnormal lipid profile was defined as TC ≥ 200 mg/dL,
HDL-c < 40 mg/dL, LDL-c ≥ 130 mg/dL, TG ≥ 150 mg/dL
and TC/HDL-c ratio ≥ 5 [9].
Ethical considerations
Ethical Clearance was obtained from the Institutional Re-
view Board of the Faculty of Health Sciences of the Univer-
sity of Buea (Reference No 2014–02–0193). Administrative
authorization was obtained from the Regional Delegation
of the Ministry of Public Health and the District Health
Services. The purpose of the study and the role of the
participants were well explained in the consent form to the
participants and participation could only take place after
the participant had read and signed the informed consent
form voluntarily.
Data analysis
Data entry and Database management was computed using
Microsoft excel 2010 (Microsoft Corporation Inc, USA).
Statistical analyses were done using STATA version 10.1.
Chi-square test was used to evaluate differences in fre-
quency distribution. Student’s t-test and analysis of variance
(ANOVA) were used to assess differences between group
means. A single model logistic regression was computed to
determine the association of independent factors with
abnormal level of each lipid profile. P-value less than 0.05
were considered as statistically significant at 95 % confi-
dence level.
Results
Demographic characteristics of participants
A total number of 209 participants were enrolled in the
study, with 51 (24.4 %) males and 158 (75.6 %) females.
Two groups of patients were investigated: the first group
of 157 HIV-infected patients [34 (21.7 %) males, 123
(78.3 %) females], were currently receiving HAART; the
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second group of 52 HIV-infected patients [17 (32.7 %)
males, 35 (67.3 %) females], were HAART inexperienced.
The mean age of individuals who were on HAART was
44.9 (±10.7) years while that of pre-HAART was 38.8
(±10.8) years (Table 1). The distribution of first-line ART
regimens were as follows: AZT/3TC/NVP (80 partici-
pants), AZT/3TC/EFV (2 participants), TDF/3TC/NVP
(21 participants) and TDF/3TC/EFV (41 participants).
The second-line ART regimen was TDF/3TC/LPVr with
13 participants. Among HAART patients, 82 (52.2 %)
were on zidovudine (AZT), 75 (47.8 %) on tenofovir
(TDF), 101 (64.3 %) on nevirapine (NVP), 43 (27.4 %) on
efavirenz (EFV) and 13 (8.3 %) on lopinavir (LPVr). All
regimens included 3TC. ART patients who had been on
treatment for an average of 64 (±41) months were
reported as non-defaulters within the past six months.
The mean CD4+ T cell count in the two groups was 425
(±280) cells/μl after a mean duration of HIV infection of
54.8 (±43.9) months. HAART experienced patients had
been on HAART for a mean duration of 63.7 (±41.4)
months. Thirty eight (18.2 %) patients reported drinking
alcohol but only four admitted they were current cigarette
smokers. Obesity, hypertension and diabetes mellitus were
screened in 48 (23.0 %), 46 (22.0 %) and 5 (2.4 %) of the
participants respectively (Table 1).
Dyslipidemia and characteristics of lipid profiles
The mean TC and mean LDL-c were significantly higher in
patients on HAART than in HAART-naïve patients (p <
0.001). The mean TG and TC/HDL-c were significantly
higher in participants on HAART than their HAART
inexperienced counterparts (p < 0.05). There was no statis-
tically significant difference between the two groups for
mean HDL-c (Table 2). The prevalence of TC ≥ 200 mg/dL
and LDL-c ≥ 130 mg/dL were significantly higher in the
HAART treated group when compared to the pre-HAART
group. However, the prevalence of HDL-c below 40 mg/dL,
TG ≥ 150 mg/dL and TC/HDL-c ≥ 5 were not statistically
significantly different in pre-HAART group when com-
pared to those on HAART treatment (Table 2).
Table 1 General characteristics of the study population by HAART status
Variables HAART experienced Group (n = 157) HAART-naïve Group (n = 52) Total p-value
Gender Male, n(%) 34 (21.7) 17 (32.7) 51 (24.4)
Female, n(%) 123 (78.3) 35 (67.3) 158 (75.6)
Age (years) Mean ± SD 44.9 (10.7) 38.8 (10.8) 43.4 (11.0) 0.0002
21-30 years, n(%) 12 (7.6) 12 (23.1) 24 (11.5)
31-40 years, n(%) 48 (30.6) 19 (36.5) 67 (32.1)
41-50 years, n(%) 52 (33.1) 15 (28.8) 67 (32.1)
> 50 years, n(%) 45 (28.7) 6 (11.5) 51 (24.4)
BMI (kg/m2) Mean ± SD 27.0 (5.4) 25.3 (4.6) 26.6 (5.3) 0.0188
< 18 kg/m2, n(%) 3 (1.9) 1 (1.9) 4 (1.9)
18-24.9 kg/m2, n(%) 64 (40.8) 2548.1) 89 (42.6)
25.0-29.9 kg/m2, n(%) 50 (31.8) 18 (34.6) 68 (32.5)
≥ 30 kg/m2, n(%) 40 (25.5) 8 (15.4) 48 (23.0)
CD4+ T cell count* Mean ± SD 430.3 (301.2) 411 (222.5) 424.9 (280.6) 0.7389
< 200 cells\μl 20 (23.5) 6 (18.2) 26 (22.0)
200-499 cells\μl 36 (42.4) 14 (42.4) 50 (42.4)
≥ 500 cells\μl 29 (34.1) 13 (39.4) 42 (35.6)
Alcohol intake No, n(%) 131 (83.4) 40 (76.9) 171 (81.8)
Yes, n(%) 26 (16.6) 12 (23.1) 38 (18.2)
Cigarette smoking No, n(%) 154 (98.1) 51 (98.1) 205 (98.1)
Yes, n(%) 03 (1.9) 01 (1.9) 04 (1.9)
Hypertension Not present, n(%) 118 (75.2) 45 (86.5) 163 (78.0)
Present, n(%) 39 (24.8) 07 (13.5) 46 (22.0)
Diabetes Mellitus Not present, n(%) 154 (98.1) 50 (96.2) 204 (97.6)
Present, n(%) 03 (1.9) 02 (3.8) 05 (2.4)
Obesity Not present, n(%) 117 (74.5) 44 (84.6) 161 (77.0)
Present, n(%) 40 (25.5) 08 (15.2) 48 (23.0)
HAART-Highly Active Antiretroviral Therapy, CD-Cluster of differentiation, SD-Standard Deviation, *-CD4+ T cell count values available for n = 118
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Total cholesterol and triglyceride levels differed among
the HAART regimens
The mean TC was higher in patients on TDF than those on
AZT among the nucleoside reverse transcriptase inhibitor
(NRTIs) based treatment. Among the non-nucleoside re-
verse transcriptase inhibitor (NNRTIs) based treated pa-
tients, the mean TC was also higher in patients on EFV
compared to NVP. Although this was not statistically
significant, it was above the normal cut off point. The mean
TG was statistically significantly higher in patients on TDF
compared to AZT, and EFV compared to NVP (p = 0.009
and 0.004 respectively) (Table 3). No significant difference
was observed in the prevalence of lipid profile derange-
ments between patients receiving AZT compared to those
on TDF; and patients treated with EFV compared to those
treated with NVP (Table 3). No significant difference was
observed in the mean lipid derangements, and the percent-
ages between protease inhibitors (PIs) treated and non-PIs
treated patients. However, the mean TG value was slightly
higher in PIs based patients (146.8 ± 59.3) compared to
non-PIs based (114.5 ± 59.5) (p = 0.0604).
Dyslipidemia with CD4+ T cell count, hypertension,
diabetes mellitus and obesity
No significant difference was observed in the mean lipid
profile parameters in the different CD4+ T cell count
categories. HAART experienced participants with CD4+ T
cell counts < 200 cells/μl and ≥ 500 cells/μl had higher
mean TC values (227.9 (±70.7) and 230.0 (±101.7) respect-
ively. No significant difference was found between mean
values of lipid derangements and presence or absence of
hypertension and diabetes mellitus. However, hypertensive
patients had higher mean values of raised TC (203.1 ±
80.6) compared to non-hypertensive (190.6 ± 68.3) (p =
0.2942). Obese patients had higher mean values of raised
TC (218.4 ± 83.1) compared to the non-obese (185.9 ±
65.7) (p = 0.0052). Also, obese patients had higher mean
values of LDL-c (128.5 ± 76.5) compared to the non-obese
(97.7 ± 61.7) (p = 0.0045).
Association of gender, BMI, HIV duration and HAART use
with abnormal lipid profiles
The female gender was significantly and positively asso-
ciated with raised TC (OR: 2.03, 95 % CI: 1.03-4.98, p =
0.042). The BMI of 25 kg/m2 and higher was signifi-
cantly associated with raised TG (OR: 0.30, 95 % CI:
0.12-0.75, p = 0.010). The duration of HIV infection of
42 months and higher was significantly associated with
raised TC and increased TG (p = 0.045 and 0.035 re-
spectively). The odds ratio (95 % CI) of HIV infection
duration of 42 months and higher versus less than
42 months was 0.51 (0.26-0.99) for TC ≥ 200 mg/dL
and 0.36 (0.14-0.93) for TG ≥ 150 mg/dL. Being on
HAART treatment for more than 55 months was
significantly associated with raised TC and raised TG,
with 95 % CI odds ratio of 0.47 (0.25-0.90) and 0.31
(0.13-0.74) respectively (Table 4).
Adjusting for potential confounding factors such as gen-
der, age, BMI, duration with HIV and HAART initiation,
receiving HAART was significantly and positively associ-
ated with raised TC and LDL-c (p < 0.0001 and 0.004
respectively). The adjusted odds ratio (95 %CI) of HAART-
treated versus HAART-naïve was 6.24 (2.33–17.45) for
TC ≥ 200 mg/dL and 5.28 (1.17–16.32) for LDL-c 130 mg/
dL. Antiretroviral therapy was not positively associated with
decreased HDL-c, increased TG and raised TC/HDL-c
ratio (p = 0.904, 0.762 and 0.188 respectively). Raised body
mass index (BMI ≥ 25.0 kg/m2) was significantly and posi-
tively associated with increased TG (aOR: 3.25, 95 %CI:
1.44-7.34, p = 0.005). The duration of HIV infection of
42 months and higher was significantly and positively asso-
ciated with raised TC (aOR: 2.26, 95%CI: 1.16-4.42, p =
0.017). HAART treatment was positively associated with
Table 2 Serum lipid profiles of study participants by HAART status
Parameters HAART experienced Group (n = 157) HAART naïve Group (n = 52) p-value
Total cholesterol, mean ± SD 208.7 (71.9) 147.4 (44.6) < 0.0001
≥ 200 mg/dL 80 (51.0 %) 5 (9.6 %) < 0.0001
LDL-cholesterol, mean ± SD 117.6 (68.2) 65.9 (42.0) < 0.0001
≥ 130 mg/dL 58 (36.9 %) 4 (7.7 %) 0.0001
HDL-cholesterol, mean ± SD 67.0 (62.6) 62.5 (26.3) 0.6153
< 40 mg/dL 22 (14.0 %) 7 (13.5 %) 0.9257
Triglycerides, mean ± SD 117.2 (59.3) 97.7 (57.5) 0.0396
≥ 150 mg/dL 32 (20.4 %) 9 (17.3 %) 0.6257
TC/HDL-cholesterol ratio, mean ± SD 3.7 (2.6) 2.8 (1.7) 0.0205
≥ 5 24 (15.3 %) 3 (5.8 %) 0.0769
HAART- Highly Active Antiretroviral Therapy, TC-Total Cholesterol; HDL-High-Density Lipoprotein, LDL-Low- Density Lipoprotein, SD-Standard Deviation
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the ratio of TC/HDL-c but this was not significant
(Table 5).
Discussion
The aim of this study conducted in a resource-poor setting
was to determine the prevalence of dyslipidemia and deter-
mining factors of derangements in lipid profile associated
with the use of HAART regimens in HIV/AIDS patients.
We found that CD4+ T cell count in the HAART group
was higher but not significantly different from the HAART-
naïve group. Though not significantly different, this shows
the effects of HAART in improving the immunological
properties of the HIV treated participants. Our finding is
contrary to that observed by D’Ascenzo and colleague [10]
where CD4+ T cell count of < 200 cells/μl was associated
with increased risk of myocardial infarction and cardiovas-
cular instability. The reason for lack of association between
lipid parameters in our cohort of HIV/AIDS patients and
the immune status may be related to the close similarity in
the CD4+ T cell count as most patients were in the CD4+ T
cell count range 200–499 cells/μl and above. The study has
demonstrated a high prevalence of lipid derangements
(64.3 %) in HIV patients receiving HAART. Though high,
the prevalence of dyslipidemia in our study is similar to the
reported rate of 70.2 % in patients receiving ART in a rural
Cameroonian population [11], but lower than that ob-
served in an urban population of Southern Ethiopia with
82.3 % [12], and 76.0 % observed in HAART-naïve
patients in Tanzania [13]. We found that the proportions
of hypercholesterolemia and raised levels of LDL-c were
significantly higher in the HAART group compared to the
HAART-naïve group. The described raised lipid profiles
(TC and LDL-c) are atherogenic [9, 14], and were still
present even after adjusting for confounders and suggests
a potential risk for the development of cardiovascular
diseases in a significant proportion of HIV-infected pa-
tients in the near future. We found that the prevalence of
raised TC in the HAART group was high. This prevalence
is higher than that reported from two similar studies in
Cameroon [11, 15], and that found in rural Ugandans [8],
where participants were followed for 24 months for lipid
derangements. More than 50 % of our HAART experienced
participants were either overweight or obese and this might
have a contributing factor on raised TC. Moreover, the
Table 3 Prevalence of abnormal lipid profiles among patients treated with NRTIs and NNRTIs based antiretroviral regimens
NRTIs based regimens
Lipid profile AZT based (n = 82) TDF based (n = 75) p-value
Total cholesterol, mean ± SD 205.2 (66.3) 212.3 (77.8) 0.540
≥ 200 mg/dL 41 (50.0 %) 39 (52.0 %) 0.802
LDL-cholesterol, mean ± SD 115.9 (63.2) 119.5 (73.6) 0.744
≥ 130 mg/dL 27 (32.9 %) 31 (41.3 %) 0.276
HDL-cholesterol, mean ± SD 70.1 (29.9) 63.7 (25.6) 0.153
< 40 mg/dL 13 (15.9 %) 9 (12.0 %) 0.482
Triglycerides, mean ± SD 102.4 (46.9) 133.4 (67.1) 0.009
≥ 150 mg/dL 12 (14.6 %) 20 (26.7 %) 0.060
TC/HDL-cholesterol ratio, mean ± SD 3.6 (2.7) 3.9 (2.4) 0.405
≥ 5 12 (14.6 %) 12 (16.0 %) 0.808
NNRTIs based regimens
NVP based (n = 101) EFV based (n = 43)
Total cholesterol, mean ± SD 204.1 (65.5) 218.7 (90.6) 0.282
≥ 200 mg/dL 49 (48.5 %) 23 (53.5 %) 0.583
LDL-cholesterol, mean ± SD 114.6 (61.2) 126.5 (87.7) 0.353
≥ 130 mg/dL 36 (35.6 %) 17 (39.5 %) 0.657
HDL-cholesterol, mean ± SD 68.3 (29.5) 63.8 (22.5) 0.370
< 40 mg/dL 17 (16.8 %) 3 (7.0 %) 0.119
Triglycerides, mean ± SD 105.4 (29.5) 136.0 (75.4) 0.004
≥ 150 mg/dL 15 (14.9 %) 12 (27.9 %) 0.068
TC/HDL-cholesterol ratio, mean ± SD 3.6 (2.7) 3.9 (2.3) 0.635
≥ 5 16 (15.8 %) 7 (16.3 %) 0.940
HAART- Highly Active Antiretroviral Therapy, TC-Total Cholesterol, HDL-High-Density Lipoprotein, LDL-Low- Density Lipoprotein, AZT-Zidovudine, TDF-Tenofovir,
NVP-Nevirapine, EFV-Efavirenz, SD-Standard Deviation
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mean TC was also significantly higher in the obese partici-
pants compared to the non-obese. However, there are
suggestions that the magnitude of HAART induced lipid
derangements could vary across populations and settings.
The prevalence of high LDL-c in our study was lower than
that reported in urban Cameroon (43.5 %) [15], but higher
than that observed in rural Cameroon (33.3 %) [11], and
similar to the prevalence reported from India [16]. How-
ever, the mean LDL-c was significantly higher in the obese
participants compared to the non-obese. The prevalence of
raised TG in our study was lower than that reported in an
urban Cameroon study (46.4 %) [15], and in the rural
Cameroon setting (51.8 %) [11], and India [16], but similar
to that reported in Kenya [17]. We found comparable
percentages of HAART experienced group (14.0 %) and
pre-HAART (13.5 %) who had decreased HDL-c. The
HDL-c level was unaffected by HAART status in our study
which is not in accordance with the findings of Pujari and
colleagues [18] in whose study an 18-month treatment with
first-line ART regimens was associated with significant
increase in HDL-c level.
Several studies have found that stavudine was more
involved in the occurrence of lipid derangements as
compared with other NRTIs [19–22]. However, instead
of stavudine, our participants were either on tenofovir or
zidovudine. We found no difference in lipid profiles
(TC, LDL-c and HDL-c) when participants on tenofovir
were compared to those on zidovudine. This is in line with
the findings of Buchacz and colleagues in Uganda [8], and
those of Yone and colleagues in Cameroon [15]. We
observed significantly higher TG in patients on tenofovir
compared to those on zidovudine. Most of the patients on
tenofovir were also on lopinavir, a protease inhibitor that
has been associated with adverse lipid profiles [23, 24]. In
line with the reports from rural Uganda [8], Cameroon
[15] and India [4], we found no significant difference in
lipid profiles (TC, LDL-c and HDL-c) of patients on
efavirenz compared to those on nevirapine. In the present
study, the raised TC and LDL-c were significantly and
positively associated with the use of HAART treatment,
and the findings are in line with another study conducted
in Cameroon [15]. Moreover, NNRTIs have been reported
to derange lipid profiles during therapy [25]. However,
supportive evidences are very scarce in Sub-Sahara Afri-
can countries concerning lipid derangements in patients
receiving NNRTIs treatment regimens [8, 26]. We found a
similar scenario with other cross-sectional studies [11, 15,
27] carried out in resources-constrained settings with
Table 4 Association of variables with abnormal lipid profile levels among HAART treated participants
Explanatory variables TC ≥ 200 mg/dL
UOR (95 % CI)
LDL-c ≥ 130 mg/dL
UOR (95 % CI)
HDL-c < 40 mg/dL
UOR (95 % CI)
TG ≥ 150 mg/dL
UOR (95 % CI)
Gender (Female) 2.3 (1.03-4.98) 1.29 (0.58-2.89) 0.54 (0.20-1.44) 0.52 (0.22-1.25)
p-value 0.042 0.532 0.217 0.144
Age > 40 years 0.81 (0.43-1.56) 1.18 (0.61-2.31) 0.93 (0.36-2.37) 0.70 (0.30-1.60)
p-value 0.535 0.621 0.879 0.391
BMI ≥ 25 kg/m2 0.80 (0.42-1.51) 0.82 (0.43-1.59) 0.92 (0.37-2.30) 0.30 (0.12-0.75)
p-value 0.490 0.558 0.857 0.010
CD4+ T cell count < 200 cells/μl 0.80 (0.29-2.17) 0.72 (0.26-1.97) 0.58 (0.13-2.55) 0.64 (0.17-2.36)
p-value 0.652 0.518 0.468 0.506
HIV duration ≥ 42 months 0.51 (0.26-0.99) 0.59 (0.29-1.18) 0.66 (0.24-1.79) 0.36 (0.14-0.93)
p-value 0.045 0.136 0.413 0.035
HAART duration
> 55 months
0.47 (0.25-0.90) 0.58 (0.30-1.11) 0.77 (0.31-1.92) 0.31 (0.13-0.74)
p-value 0.022 0.101 0.572 0.008
Hypertension 1.02 (0.49-2.10) 0.94 (0.44-2.00) 0.87 (0.30-2.54) 0.81 (0.32-2.06)
p-value 0.962 0.876 0.805 0.664
Diabetes Mellitus 0.47 (0.04-5.34) 0.85 (0.08-9.59) NA 8.27 (0.73-94.2)
p-value 0.546 0.896 NA 0.089
Obesity 1.88 (0.90-3.92) 2.08 (1.00-4.32) 1.11 (0.40-3.08) 1.44 (0.61-3.38)
p-value 0.093 0.050 0.835 0.403
Alcohol intake 1.38 (0.59-3.24) 0.72 (0.29-1.78) 1.14 (0.35-3.70) 2.49 (0.99-6.27)
p-value 0.453 0.476 0.825 0.054
TC-Total Cholesterol, LDL-c-Low-Density Lipoprotein Cholesterol, HDL-c-High-Density Lipoprotein Cholesterol, TG-Triglyceride, HAART-Highly Active Antiretroviral
Therapy, UOR-Unadjusted Odds Ratio, BMI-Body Mass Index, CD-Cluster of differentiation, NA- not applicable; Reference category: Male, Age ≤ 40 years, BMI <
25 kg/m2, CD4+ T cell count ≥ 200 cells/μl, HIV duration < 42 months, HAART duration ≤ 55 months, non-hypertensive, non-diabetic, non-obese, no alcohol intake
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reported prevalence of high level of total cholesterol ran-
ging from 23 to 41 % in patients treated with NNRTI
based regimens [27].
The association between HAART and adverse lipid pro-
file has been largely described for regimens that include PIs
[23, 24], but this is contrary to our findings. This may be
due to the small number of patients treated with PIs in our
study. In this study, high TC and LDL-c were associated
with HAART use. High TC was also associated with age
>40 years, but was no association could be found after
adjusting for confounding factors. The association of high
TC with age is well known as its risk increases with
increased age [13, 28].
There is lack of data on HIV viral load to clearly define
disease stages in the two groups. However, the CD+ T
cell counts gave a snapshot of disease progression in the
untreated group and disease suppression in the treated
group. Comprehensive cardiovascular risk stratifications
were not assessed in this study. However, the increased
risk of atherothrombotic cardiovascular disease associ-
ated with the described lipid derangement is well known
[8, 29] and the long term use of HAART may have an
impact on cardiovascular health. Our study, by nature is
cross-sectional and inference about causal relationship is
not possible. Cohort studies could monitor lipid profile
alterations during HAART, and their potential impact on
cardiovascular health of people living with HIV. Subsequent
studies could address the issue of the small number of male
participants, small number of patients in the HAART un-
treated group, and the lack of HIV-negative controls that
our study could not handle.
Conclusion
This study indicates that HIV-infected patients receiving
WHO-recommended HAART treatment have a high
prevalence of lipid profile derangements when compared
to the HAART non-treated HIV-infected patients. Uses
of HAART regimens are significantly associated with
atherogenic lipid profiles. Lipid profile and other cardio-
vascular risk factors should be monitored in patients on
ART so that any negative effects of HAART can be opti-
mally managed. We recommend the implementation of
well controlled cohort studies for the evaluation of long-
term effects of HAART treatment on lipid profiles.
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Table 5 Association of HAART and other variables with dyslipidemia among HIV-infected patients
Explanatory Variables TC ≥ 200 mg/dL
AOR (95 % CI)
LDL-c ≥ 130 mg/dL
AOR (95 % CI)
HDL-c < 40 mg/dL
AOR (95 % CI)
TG≥ 150 mg/dL
AOR (95 % CI)
TC/HDL-c ≥ 5
AOR (95 % CI)
Antiretroviral therapy
HAART-naïve* 1.00 1.00 1.00 1.00 1.00
HAART treated 6.24 (2.33-17.45) 5.28 (1.17-16.32) 1.07 (0.37-3.05) 0.86 (0.32-2.28) 2.51 (0.64-9.89)
p-value < 0.001 0.004 0.904 0.762 0.188
Gender
Male* 1.00 1.00 1.00 1.00 1.00
Female 2.17 (0.99-4.74) 1.20 (0.55-2.65) 0.45 (0.19-1.07) 0.44 (0.19-1.01) 0.42 (0.16-1.09)
p-value 0.053 0.645 0.071 0.054 0.076
Age group
≤ 40 years* 1.00 1.00 1.00 1.00 1.00
> 40 years 1.11 (0.58-2.31) 0.91 (0.47-1.78) 0.80 (0.35-1.84) 1.22 (0.57-2.58) 1.02 (0.42-2.46)
p-value 0.746 0.789 0.605 0.611 0.963
Body Mass Index
BMI < 25 kg/m2* 1.00 1.00 1.00 1.00 1.00
BMI ≥ 25 kg/m2 0.98 (0.52-1.86) 1.07 (0.56-2.05) 0.88 (0.39-1.98) 3.25 (1.44-7.34) 2.19 (0.87-5.51)
p-value 0.962 0.845 0.757 0.005 0.097
HIV duration
< 42 months* 1.00 1.00 1.00 1.00 1.00
≥ 42 months 2.26 (1.16-4.42) 1.71 (0.85-3.45) 1.32 (0.53-3.29) 1.89 (0.81-4.41) 1.58 (0.60-4.13)
p-value 0.017 0.133 0.0.545 0.140 0.350
TC-Total Cholesterol, LDL-c-Low-Density Lipoprotein Cholesterol, HDL-c-High-Density Lipoprotein Cholesterol, TG-Triglyceride; HAART-Highly Active Antiretroviral
Therapy, AOR-Adjusted Odds Ratio, BMI-Body Mass Index; *-Reference category
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PI: Protease Inhibitor; NNRTI: Non-Nucleoside Reverse Transcriptase Inhibitor;
NRTI: Nucleoside Reverse Transcriptase Inhibitor; CD4+: Cluster of Differentiation.
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